Navigation Links
The European Myeloma Platform Reports New Survival data for,Revlimid Presented at the International Myeloma Workshop in Greece

BRUSSELS, Belgium and KOS, Greece, June 29, 2007 /PRNewswire/ -- The European Myeloma Platform (EMP) says updated data for previously treated patients on REVLIMID (lenalidomide) plus the steroid dexamethasone shows median survival of 35 months, nearly three years. The data are pooled from two large randomized controlled Phase III trials that enrolled more than 700 patients from nearly 100 clinical sites worldwide. These updated results were presented at the 11th International Myeloma Workshop in Kos, Greece.

"Here in Kos we are seeing what is truly a paradigm shift in treatment for multiple myeloma patients," said Greetje Goossens, EMP member and leader of the Belgium myeloma support group. "The experts here are saying that nearly three years of median over all survival for REVLIMID patients is the longest they have seen in myeloma to-date from large clinical trials."

This is the first major medical meeting since REVLIMID, an oral breakthrough therapy, was approved in Europe earlier this month for multiple myeloma patients. It has been approved for the past year in the United States. Previously it was reported that for newly diagnosed patients in a large randomized Phase III trial, REVLIMID with low dose dexamethasone demonstrated an unprecedented 98% one year survival in patients under 65 and 95% one year survival in patients 65 and over. Investigators characterized this as the best one-year survival data they have seen in a large phase 3 study in myeloma.

"We are very excited about these data," said Dr. Rolf Pelzing of Germany, Vice-Chairperson, EMP. "There is no cure for myeloma, but from personal experience, I can say that the duration of survival and the quality of life is improving significantly for many of us as demonstrated by the powerful new data that were presented at the meeting in Kos."

Multiple myeloma is a rare form of cancer of plasma cells. It is the second most comm on cancer of the blood, affecting over 80,000 people in Europe and an estimated 750,000 worldwide at any one time. EMP is a European umbrella organization of myeloma patient support groups. EMP has been working to help make REVLIMID available throughout Europe, and members of the organization continue to work with local regulatory agencies to help secure local reimbursement approvals.

    For more information, contact:

    Dr. Rolf Pelzing


CONTACT: Dr. Rolf Pelzing, +49-2151-305170, , forEuropean Myeloma Platform

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Malvern initiates European user group meetings for chemical imaging
6. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
7. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
8. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
9. Inspire Announces Presentations at Two European Scientific Conferences
10. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
11. Archimedes Pharma Presents Positive Efficacy and Safety Data on Nasalfent at European Association for Palliative Care Congress
Post Your Comments:
(Date:11/29/2015)... 2015 CIVCO Medical Solutions will demonstrate ... Radiological Society of North America ... November 29 – December 4, 2015. The ... customers unrivaled versatility, enhanced user experience and deliver ... --> --> ...
(Date:11/27/2015)... YORK , November 27, 2015 ... system is set to go online. The potential to ... processes is vast and far from fully exploited as ... to patient health records, either via mobile tablet or ... ) --> ) --> ...
(Date:11/27/2015)... , Nov. 27, 2015 Research and Markets ... "Global Intrauterine Devices Market 2015-2019" report to ... --> In this report, the author the present ... market for 2015-2019. To calculate the market size, the ... type of products: Hormonal IUDs and copper IUDs. The ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 28, 2015 , ... There is only one major question facing all law ... , This question has not been an easy question to answer. Especially when the ... the younger workforce don’t share the same discipline around working long hours. , ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... According to ... out by the University of Toronto and the University of British Columbia suggested that ... for head injuries. The article explains that part of the reason for the controversial ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... affecting the health care in America. As people age, more care is needed, ... costs are rising, and medical professionals are being overworked. The forgotten part of ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... safe and convenient way to dispense prescription medications at home, so he invented ... way to monitor and dispense prescription medications. In doing so, it could help ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just ... is offering customers 10% off of their purchase of lice treatment product. In addition, ... price. According to a company spokesperson. “Finding lice is a sure way to ruin ...
Breaking Medicine News(10 mins):